Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Single-cell mitophagy signature-based artificial intelligence model enhances prediction of prognosis and immunotherapy response in non-small-cell lung cancer.
PMID 41851738 · PMC13112628 · Respiratory research · 2026 · 8 claims · 8 setups
A six-gene MRG panel (FOS, CANX, EIF4G1, CALCOCO2, HSP90AB1, PRKAR1A) was selected via LASSO regression as prognostic markers in NSCLC.
-
Full-text index only
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
PMID 17047648 · PMC2360715 · British journal of cancer · 2006 · 7 claims · 5 setups
Gefitinib is highly active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations
-
Has reproduction · 40
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127(+) and KLRG1(+) CD8 T cells.
PMID 37231145 · PMC10213055 · NPJ precision oncology · 2023 · 8 claims · 5 setups
NAPC produces higher major pathological response (MPR) and pathological complete response (pCR) rates and longer DFS/OS than NAC alone